NP001 is designed to tackle the neurodegenerative disease through an immunologic...
The safety review was requested by the French medicines agency, citing new safet...
The company intends to start a registrational Phase II trial of pelareorep and c...
US hedge fund Starboard now holds 0.6% of Pfizer’s value as the drugmaker strugg...
ProductLife Group (PLG) has announced the acquisition of IntiQuan, a Swiss firm ...
Health Canada has expanded the approved use of Telix Pharmaceuticals' Illuccix f...
OnKure has announced the successful completion of its merger with Reneo Pharmace...
The CD7 CAR)-T cell therapy has demonstrated potential in treating patients with...
Teva Pharmaceuticals International and mAbxience have entered into a worldwide l...
Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Admin...
National Resilience’s subsidiary Resilience Government Services has received aro...
At ELRIG 2024, Dr. Maria Duca described how her lab’s rational design approach b...
WuXi is considering the sale of some US and European operations to mitigate the ...
It is common for sponsors to switch digital platforms between clinical trial pha...
Two years after the FDA placed partial clinical hold, Avidity can resume researc...
